Claire Schmidt
Optometrist · Apo, AENPI 1821254236
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $234 and has fallen 55.6% since, to $104 in 2025.
Across 22 payments — averaging $29.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$121
- Johnson & Johnson Vision Care, Inc.$96
- Novartis$96
- Alcon$79
- Tarsus Pharmaceuticals, Inc.$73
- Oyster Point Pharma, Inc.$49
- plus $129 from 4 others
What the payments were for
- Food & beverage$643100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 1 | $121 |
| Johnson & Johnson Vision Care, Inc. | 4 | $96 |
| Novartis | 5 | $96 |
| Alcon | 2 | $79 |
| Tarsus Pharmaceuticals, Inc. | 2 | $73 |
| Oyster Point Pharma, Inc. | 2 | $49 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $47 |
| Coopervision Inc. | 2 | $46 |
| Biotissue Holdings Inc. | 1 | $20 |
| AbbVie | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INFUSE$121
How this compares
Too few optometrist providers in AEto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Latanoprost | 44 | $573 |
| Timolol Maleate | 24 | $366 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Apo
- Diana PustApo$5K
- Elizabeth FahyApo$2K
- Cam-Van le CarrellApo$1K
- Michael TommolinoApo$1K
- Clarence VeselyApo$453
- Jared NelsonApo$334
- Christopher AlferezApo$180
- John BradleyApo$176
- Sarah GanzApo$150
- Antione BarnettApo$122
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.